Agilent Joins the National Institute for Innovation in Manufacturing to Advance Biomanufacturing
Support for biologics manufacturability and Industry 4.0 initiatives
The biomanufacturing industry is increasingly interested in continuous manufacturing solutions that can reduce the manufacturing footprint and improve supply chain logistics and biotherapeutic access by enabling manufacturing to move closer to patients, especially in underserved areas. The NIIMBL mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, which will fundamentally advance
“Agilent has long played a key role in providing trusted answers for the analytical needs of the biopharmaceutical industry,” said Agilent CEO
Agilent’s online HPLC sampling portfolio, cellular imaging, and real-time sensor technologies exemplify how the company can help address current and emerging needs. Additionally, Agilent’s NIIMBL membership will allow us to work closely with all continuum partners to help shape the future of innovation and standards used in bioprocess development and biomanufacturing.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005201/en/
+1.781.266.2819
naomi.goumillout@agilent.com
Source: